Regulatory T cell suppress cytotoxic T cells in autoimmunity and cancer by taking up IL-2.

COVID-19 mRNA vaccine-elicited T cells recognize variants of concern and phenotypically differ depending on number of vaccine doses and prior SARS-CoV-2 infection status.

Cross-reactive T cell immunity against the SARS-CoV-2 is severely compromised in HIV viremic individual.

Cell culture adaptation of SARS-CoV-2 is prevented on human airway cells with an active serine protease-mediated entry pathway, allowing the production of genetically stable virus stocks for laboratory experiments.

In the context of SARS-CoV-2 infection, Nsp14 alters gene expression of the host cell through the interaction with the cellular enzyme IMPDH2.

A panel of interleukin-2 partial agonists designed to exploit distinct immune cell response thresholds enabled selective activation of regulatory T cells in vivo.

Influenza-induced pulmonary tuft cells are a heterogenous population and emerge independently of Type 2 and interferon signaling, and do not impact dysplastic epithelial regeneration.

A membrane-associated, supramolecular protein complex with dynamically changing components, the central supramolecular activation cluster, regulates the generation of the T cell effector cytokine IL-2 depending on its composition.

Knocking out Folliculin (FLCN) in human renal epithelial cells activates STAT1/2-mediated gene expression, independent of interferon, uncovering a tissue-specific process potentially relevant in the cancer syndrome Birt-Hogg-Dubé (BHD).

The prolyl hydroxylase domain 2 regulates the Treg development and function in a hypoxia-inducible factor 2α-dependent manner.